Chinese Medicine in combination with western medicine for the prevention of relapse in patients with severe psoriasis

Chinese herbal medicine (Gu-Ben Hua-Yu-fang) in combination with ixekizumab for the prevention of relapse in patients with severe psoriasis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032847

Enrollment

Unknown

Registered

2020-05-13

Start date

2020-05-15

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

Case series:oral Chinese herbal medicine (Gu ben hua yu fang) in combination ixekizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients with psoriatic lesions area and severity index PASI = 10 met the diagnostic criteria of severe psoriasis; 2. Patients who meet the indications of biological agents (iqizhu) and have no history of inflammatory bowel disease (IBD); 3. Patients who sign informed consent.

Exclusion criteria

Exclusion criteria: Psoriasis patients not suitable for iqizhu treatment.

Design outcomes

Primary

Measure	Time frame
Time to relapse;	—

Secondary

Measure	Time frame
The improvement in PASI score from baseline after treatment;The proportion of patients who achieve at least 75% improvement in PASI score from baseline;The proportion of patients who achieve at least 90% improvement in PASI score from baseline;Physician's global assessment (PGA) score;Pruritus Scores on the Visual Analogue Scale;Body Surface Area;Dermatology Life Quality Index (DLQI);Skindex16;	—

Countries

China

Contacts

Public ContactChuanjian Lu

Guangdong Hospital of traditional Chinese Medicine

luchuanjian888@vip.sina.com+86 13822250116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026